I-Mab Receives Top Rankings in Five Categories by Institutional Investor

GAITHERSBURG, MD. and SHANGHAI, China – June 23, 2022 – I-Mab (“I-Mab” or the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it was ranked among the top companies in five different categories by leading global financial publication Institutional Investor, based on its 2022 All-Asia Executive Team survey. The awards recognize I-Mab’s continued strong leadership, corporate governance, ESG strategy, and investor relations capabilities.

I-Mab was recognized in the “Honored Companies,” “Best CEO,” “Best CFO,” “Best IR Professional,” “Best IR Program,” and “Best ESG” categories. This is also the second consecutive year that I-Mab has been named as the “Honored Company” within the healthcare and pharmaceuticals sector. With its globally competitive pipeline of novel or highly differentiated biologics advancing in clinical development, I-Mab has demonstrated its commitment to innovation and value creation for shareholders. The ranking by Institutional Investor signifies capital market recognition of the Company’s continued leadership in innovation and excellence in corporate governance.

The details of I-Mab’s rankings are:

  • The Company is named the “the Honored Company” in Core Asia, Mainland China and Small & Midcap results.
  • Jingwu Zang is named “Best CEO” and ranked top 3 in Mainland China sell-side, Small & Midcap overall and sell-side results.
  • John Long is named “Best CFO” and ranked top 3 in Core Asia sell-side, Mainland China sell-side, Small & Midcap overall, buy-side and sell-side results.
  • Tianyi Zhang is named “Best IR Professional” and ranked top 3 in Small & Midcap sell-side results.
  • The Company’s IR team is named “Best IR Program” and ranked top 3 in Mainland China sell-side , Small & Midcap overall and sell-side results.
  • The Company’s ESG program is recognized as top 3 “Best ESG” in Core Asia sell-side, Mainland China sell-side, Small & Midcap overall and sell-side results.

Institutional Investor is one of the industry’s most trusted global sources for research and rankings among top analysts and portfolio managers while continuing to set the standard by which excellence is measured. Institutional Investor’s “2022 All-Asia Executive Team” survey results reflect the opinions of 4,854 investors, portfolio managers, and analysts from 670 financial services firms globally, nominating a total of 1,612 companies and 2,606 individuals across 18 sectors.


About I-Mab

I-Mab (Nasdaq: IMAB) is an innovation-driven global biopharma company focused on the discovery, development and commercialization of novel and highly differentiated biologics for immuno-oncology diseases. The Company’s mission is to bring transformational medicines to patients around the world through innovation. I-Mab’s globally competitive pipeline of more than 20 clinical and preclinical-stage drug candidates is driven by its internal discovery and global partnerships for in-licensing, based on the Company’s Fast-to-Proof-of-Concept and Fast-to-Market development strategies. The Company is progressing from a clinical-stage biotech company into an innovative global specialty biopharmaceutical company with cutting-edge R&D capabilities, a world-class GMP manufacturing facility, and commercial capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States.  For more information, please visit https://www.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter, and WeChat.

Forward Looking Statements

This press release includes certain disclosures which contain “forward-looking statements.” You can identify forward-looking statements because they contain words such as “anticipate” and “expected.” Forward-looking statements are based on I-Mab’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in filings with the U.S. Securities and Exchange Commission. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.